Brief: Blueprint Medicines Presents Registrational Data From Pioneer Trial Of Ayvakit
26/02/2023 20:02
Feb 26 (Reuters) - Blueprint Medicines Corp BPMC.O :
* BLUEPRINT MEDICINES PRESENTS REGISTRATIONAL DATA FROM
PIONEER
TRIAL OF AYVAKIT® (AVAPRITINIB) IN PATIENTS WITH INDOLENT
SYSTEMIC MASTOCYTOSIS AT 2023 AAAAI ANNUAL MEETING
* AYVAKIT HAD A FAVORABLE SAFETY PROFILE COMPARED TO
PLACEBO,
SUPPORTING POTENTIAL FOR CHRONIC TREATMENT
Source text for Eikon: ID:nPn2L4NVga
Further company coverage: BPMC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Blueprint Medicines
See all newsBrief: Sanofi Announces Extension Of Blueprint Tender Offer
Brief: Blueprint Medicines Announces Data Reinforcing Safety Profile Of Long-Term Ayvakit
U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal
U.S. RESEARCH ROUNDUP-Biomea Fusion, GE Aerospace, P&G